CTA
BIIB icon

Carillon Tower Advisers’s Biogen BIIB Stock Holding History

Carillon Tower Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-7,700
Closed -$2.32M – 463
2018
Q4 		$2.32M Buy
+7,700
New +$2.46M 0.02% 424
2018
Q3 		– Sell
-8,300
Closed -$2.41M – 430
2018
Q2 		$2.41M Buy
+8,300
New +$2.33M 0.02% 430

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Carillon Tower Advisers's BIIB Position: Q1 2019 in Review

Carillon Tower Advisers sold out of Biogen (BIIB) in Q1 2019, closing a stake of 7,700 shares — an estimated $2.32M sold.

Carillon Tower Advisers first reported a position in BIIB in Q2 2018 and held it in 2 quarters. The position peaked at $2.41M in Q2 2018. 1,084 funds tracked by Wall St. Rank hold BIIB as of Q1 2019.

  • Carillon Tower Advisers reported no remaining Biogen position as of Q1 2019 after selling out during the quarter.
  • Carillon Tower Advisers sold 7,700 Biogen shares in Q1 2019, an estimated $2.32M.
  • Carillon Tower Advisers first reported a position in Biogen in Q2 2018 and held it in 2 quarters.
  • Carillon Tower Advisers's Biogen position peaked at $2.41M in Q2 2018.
  • 1,084 funds tracked by Wall St. Rank held Biogen as of Q1 2019.

Based on Carillon Tower Advisers's 13F filing for Q1 2019, filed 3 May 2019.